{"id":"W2887412253","doi":"10.1016/s0140-6736(18)31713-6","title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":662,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"Dermira; Genentech; Celgene; AbbVie; GlaxoSmithKline Australia; Bristol-Myers Squibb; Amgen; Boehringer Ingelheim","keywords":"Medicine; Ustekinumab; Placebo; Psoriasis Area and Severity Index; Internal medicine; Psoriasis; Clinical trial; Randomization; Randomized controlled trial; Gastroenterology; Dermatology; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003334084,0.0004531125,0.003195923,0.0001929256,0.0002954866,0.00006360687,0.0002809027,0.0003095127,0.0001155686],"category_scores_gemma":[0.001103346,0.0002789656,0.0001685815,0.0001752761,0.0003360117,0.0001121813,0.0001226496,0.0002529209,0.00003416836],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003141238,"about_ca_system_score_gemma":0.00006422427,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007054163,"about_ca_topic_score_gemma":0.0004513386,"domain_scores_codex":[0.9956046,0.001854674,0.001306474,0.0006527904,0.00008150827,0.0004999324],"domain_scores_gemma":[0.9928499,0.005814336,0.0005675862,0.0006105569,0.00008752284,0.00007009877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9587726,0.0002152577,0.0002021889,0.00001169042,0.001624556,0.000009011631,0.002812548,0.00004237998,0.01805523,0.00007755677,0.0005875492,0.01758941],"study_design_scores_gemma":[0.9835325,0.0005590736,0.001194691,0.0001138597,0.0009800562,0.00002766055,0.0001710735,0.0002658926,0.01183307,0.0001937558,0.0008211086,0.0003072113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873417,0.004580262,0.00005277123,0.0009428747,0.0004523095,0.004845208,0.0009188337,0.00004794331,0.0008180965],"genre_scores_gemma":[0.9967341,0.001355012,0.0002378292,0.000128803,0.0005078047,0.0002887519,0.0001937296,0.00002839494,0.0005255952],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02475993,"threshold_uncertainty_score":0.9999663,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05257706308536371,"score_gpt":0.3200678952590045,"score_spread":0.2674908321736408,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}